Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS)
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to find out if mexiletine is safe and effective in people
with Amyotrophic Lateral Sclerosis (ALS). In this trial, participants will be taking either
300 milligrams per day of mexiletine, 900 milligrams per day of mexiletine or placebo
(non-active study drug). The safety and efficacy of these doses will be compared to see if
one dose is better than the other.